Evidence map›Paper›PMID 40641019›Full record

ArticleCurrent pharmaceutical design2026

Integrated Network Pharmacology and Molecular Modeling Approach for Potential PTGS2 Inhibitors against Rheumatoid Arthritis.

Huda Abbasi, Maria Sharif, Peter John, Attya Bhatti

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huda AbbasiSchool of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.ORCID 0000-0001-5767-1137
Maria SharifSchool of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.ORCID 0000-0002-4261-5316
Peter JohnSchool of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.ORCID 0000-0003-1361-7635
Attya BhattiSchool of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.ORCID 0000-0002-2781-5221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRheumatoid arthritis (RA) is a chronic inflammatory condition of the joints and a leading cause of global disability. However, the use of current anti-inflammatory treatments is often limited by serious side effects and multi-organ toxicity, necessitating the exploration of safer alternatives.

objectiveThis study aims to investigate the anti-rheumatic potential of natural compounds of

methodsThe therapeutic potential of

results

conclusionC. angustifolia compounds present a significant potential as PTGS2 inhibitors, warranting further in vitro and in vivo investigations to confirm their therapeutic efficacy against RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidCyclooxygenase 2Cyclooxygenase 2 InhibitorsNetwork PharmacologyPlant ExtractsHumansModels, MolecularMolecular Docking SimulationMolecular Dynamics SimulationAntirheumatic AgentsCyclooxygenase 2Cyclooxygenase 2 InhibitorsPlant ExtractsPTGS2 protein, humanADMETCassia angustifoliainflammationmolecular dynamics simulation.network pharmacologyRheumatoid arthritis

Identifiers

PMID40641019

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.